Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma

Malignant melanoma is associated with poor clinical prognosis; however, novel molecular and immune therapies are now improving patient outcomes. Almost 50% of melanomas harbor targetable activating mutations of BRAF which promote RAS-RAF-MEK-ERK pathway activation and melanoma proliferation. Recent...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Ther
Autori principali: Ilieva, Kristina M., Correa, Isabel, Josephs, Debra H., Karagiannis, Panagiotis, Egbuniwe, Isioma U., Cafferkey, Michiala J., Spicer, James F., Harries, Mark, Nestle, Frank O., Lacy, Katie E., Karagiannis, Sophia N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4258403/
https://ncbi.nlm.nih.gov/pubmed/25385327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0290
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi